{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:49:26Z","timestamp":1770230966568,"version":"3.49.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.2169\/internalmedicine.4807-24","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:11:51Z","timestamp":1738948311000},"page":"2386-2389","source":"Crossref","is-referenced-by-count":1,"title":["Pseudo-hyperprogression of Malignant Pleural Mesothelioma Treated with Nivolumab"],"prefix":"10.2169","volume":"64","author":[{"given":"Masaaki","family":"Yanai","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"},{"name":"Cancer Center, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Nakada","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Teruya","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Funaki","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Harada","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kodani","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"},{"name":"Cancer Center, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fennell DA, Ewings S, Ottensmeier C, et al.; the CONFIRM trial investigators. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 22: 1530-1540, 2021.","DOI":"10.1016\/S1470-2045(21)00471-X"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397: 375-386, 2021.","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wolchok JD, Hoos A, O&apos;Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420, 2009.","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Li N, Wang G, Hou X, et al. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. Int Immunopharmacol 108: 108803, 2022.","DOI":"10.1016\/j.intimp.2022.108803"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol 30: 385-396, 2019.","DOI":"10.1093\/annonc\/mdz003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Barnet MB, Zielinski RR, Warby A, Lewis CR, Kao S. Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. J Thorac Oncol 13: e1-e2, 2018.","DOI":"10.1016\/j.jtho.2017.09.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shen P, Han L, Ba X, Qin K, Tu S. Hyperprogressive disease in cancers treated with immune checkpoint inhibitors. Front Pharmacol 12: 678409, 2021.","DOI":"10.3389\/fphar.2021.678409"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ferrara R, Signorelli D, Proto C, Prelaj A, Garassino MC, Lo Russo G. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Transl Lung Cancer Res 10: 2955-2969, 2021.","DOI":"10.21037\/tlcr-20-636"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E. Pseudoprogression and hyperprogression as new forms of response to immunotherapy. BioDrugs 34: 463-476, 2020.","DOI":"10.1007\/s40259-020-00425-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 28: 3316-3322, 2010.","DOI":"10.1200\/JCO.2009.26.9944"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kiriu T, Yamamoto M, Nagano T, et al. Pseudo-progression and the neutrophil-to-lymphocyte ratio in non-small cell lung cancer treated with immune checkpoint inhibitors: a case-control study. Onco Targets Ther 12: 10559-10568, 2019.","DOI":"10.2147\/OTT.S228138"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 4: 717-721, 2018.","DOI":"10.1001\/jamaoncol.2017.5332"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Guibert N, Mazieres J, Delaunay M, et al. Monitoring of <i>KRAS<\/i>-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget 8: 38056-38060, 2017.","DOI":"10.18632\/oncotarget.16935"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 28: 1988-1995, 2017.","DOI":"10.1093\/annonc\/mdx190"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matsuo N, Azuma K, Hattori S, et al. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. Int J Cancer 144: 1170-1179, 2019.","DOI":"10.1002\/ijc.31923"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen MY, Zeng YC. Pseudoprogression in lung cancer patients treated with immunotherapy. Crit Rev Oncol Hematol 169: 103531, 2022.","DOI":"10.1016\/j.critrevonc.2021.103531"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19: 3936-3943, 2013.","DOI":"10.1158\/1078-0432.CCR-13-0895"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Seymour L, Bogaerts J, Perrone A, et al.; the RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18: e143-e152, 2017.","DOI":"10.1016\/S1470-2045(17)30074-8"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4807-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:16:07Z","timestamp":1754108167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4807-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4807-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"4807-24"}}